Albert Oriol
Institut Català d'Oncologia - Hospital Germans Trias i Pujol
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Albert Oriol as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07901868 · Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaPETHEMA Foundation · not yet recruiting · Multiple Myeloma Refractory, Multiple Myeloma in Relapse · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:49 UTC. The ranking covers the 200 most relevant of 157 PubMed records, and a shared surname and initials can bring in a namesake. All 157 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med · 20161,208 citationsRCR 41.0
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med · 20151,133 citationsRCR 36.3
- Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20221,126 citationsRCR 79.2
- 981 citationsRCR 24.4
- 756 citationsRCR 25.0
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J Med · 2023749 citationsRCR 61.8
- 715 citationsRCR 23.2
- 670 citationsRCR 18.7
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.N Engl J Med · 2022670 citationsRCR 46.2